NewCardio, Inc. is a cardiac diagnostic technology provider which focuses on the research, development and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular diseases, as well as the cardiac safety assessment of drugs under development. It engages in development of three solutions through 3D platform technology, which includes, QTinno, is an automated cardiac safety solution that streamlines the process for meeting the early phase cardiac safety analysis; CardioBip, is a wireless transtelephonic system which engages in delivering remote diagnosis and review of patients with chronic cardiac conditions and my3KG, is a software application developed to assess cardiac electrical activity in time and space. NewCardio was founded on September 2, 2003 and is headquartered in Princeton, NJ.